History of GLP-1 Drugs: From Gila Monster to Blockbuster

Introduction

The modern GLP-1 drug class traces back to two unlikely starting points: the discovery of the GLP-1 hormone in the 1980s and a peptide found in the venom of the Gila monster, a desert lizard. That venom peptide lasted far longer in the body than human GLP-1, and it became the template for the first drug in the class. From there, decades of protein engineering turned a twice-daily injection into the once-weekly blockbusters of today.

This is the story of how a gut hormone and a lizard’s venom became some of the most prescribed medications in the world. It moves through discovery, the first drugs, the engineering breakthroughs, and the moment weight loss took center stage.

At TrimRx, we believe understanding where these medications came from builds trust in using them. If a personalized GLP-1 program might fit your goals, you can take the free assessment quiz to see whether it is a match.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

How Was the GLP-1 Hormone Discovered?

GLP-1 was identified in the 1980s as scientists studied the gene that codes for glucagon and found it also produced other peptides, including glucagon-like peptide-1. Researchers soon learned this gut hormone triggered insulin release after eating.

Quick Answer: The GLP-1 drug story begins with a hormone discovered in the 1980s and a venom peptide from the Gila monster lizard.

The discovery answered an old puzzle. Doctors had long noticed that sugar taken by mouth caused a bigger insulin response than the same sugar given by vein, a phenomenon called the incretin effect. GLP-1 turned out to be a major reason. It was released by the gut in response to food and told the pancreas to release insulin, but only when blood sugar was elevated. That glucose-dependent action hinted at a safer way to treat diabetes, if only the hormone could be made to last.

Why Did the Natural Hormone Not Work as a Drug?

Natural GLP-1 was useless as a drug because the body destroyed it within about two minutes. An enzyme called DPP-4 clipped and inactivated it almost as fast as it appeared, so an injection would vanish before it could help.

This was the central obstacle. The hormone did exactly what diabetes treatment needed, raising insulin and curbing appetite, but its two-minute half-life meant a constant infusion would be required just to keep any present. Scientists faced a choice: either block the enzyme that destroyed GLP-1, which led to a different drug class, or build a version of the hormone that could survive. Both paths were eventually taken, and the second produced the GLP-1 drugs we know now.

What Role Did the Gila Monster Play?

The Gila monster, a venomous desert lizard, produces a peptide in its venom called exendin-4 that closely resembles human GLP-1 but resists the DPP-4 enzyme. Researchers realized this natural molecule could last for hours instead of minutes, making it a viable drug template.

The lizard eats infrequently, sometimes only a few times a year, and its venom peptide helps regulate its metabolism over long stretches. That durability was exactly what human medicine lacked. Scientists synthesized a version of exendin-4, named exenatide, and it became the first GLP-1 drug. The story of a desert lizard seeding a multibillion-dollar drug class is real, not marketing. It is one of the clearest examples of nature solving a problem before pharmacology did.

What Was the First GLP-1 Drug?

Exenatide, sold as Byetta, became the first GLP-1 drug approved in 2005 for type 2 diabetes. Based on the Gila monster peptide, it lasted long enough for twice-daily injection, a major improvement over the two-minute natural hormone.

Byetta proved the concept. It lowered blood sugar through the glucose-dependent mechanism, and patients also tended to lose modest weight, a side effect that drew attention. Twice-daily dosing was still a burden, though, and the search turned toward longer-acting options. A weekly version of exenatide followed, but the bigger advances came from a different approach: building human GLP-1 itself into a durable molecule rather than copying the lizard’s peptide.

How Did the Drugs Reach Once-weekly Dosing?

Once-weekly dosing came from engineering GLP-1 analogs with a fatty acid chain that binds albumin in the blood, dramatically slowing clearance. Liraglutide stretched dosing to once daily, and semaglutide pushed it to once weekly.

Liraglutide, approved for diabetes as Victoza® and later for weight as Saxenda®, was the first to use the albumin-binding strategy, achieving daily dosing. Semaglutide refined the design further, adding a fatty acid anchor, an amino acid swap to resist DPP-4, and a linker to hold it together. The result was a roughly 7-day half-life. This engineering, more than any single discovery, is what turned GLP-1 drugs from a niche diabetes option into something patients could fit into their lives with one weekly injection.

When Did Weight Loss Become the Headline?

Weight loss became the headline in the early 2020s, when trials designed specifically for obesity showed dramatic results. The STEP program for semaglutide (Wilding 2021, NEJM) demonstrated weight reductions far beyond older weight drugs.

Until then, weight loss had been a welcome side effect noted in diabetes trials. The STEP trials changed the framing by testing semaglutide at higher doses in people with obesity, and the average results were striking. This led to Wegovy®, the brand semaglutide approved specifically for weight management. The cultural shift was sudden. A class born to treat diabetes became defined by its weight effect, and demand exploded, eventually outpacing supply and driving the growth of compounded options.

Key Takeaway: The leap to weekly dosing came from engineering molecules like liraglutide and then semaglutide to bind albumin and resist breakdown.

What Did Tirzepatide Add to the Story?

Tirzepatide added a second receptor target, becoming the first twincretin by activating both GIP and GLP-1 with one molecule. The SURMOUNT program (Jastreboff 2022, NEJM) showed it produced even larger average weight loss.

This was the next leap. Rather than refining a GLP-1-only drug, designers built a molecule that engaged two gut hormone receptors at once. Approved as Mounjaro® for diabetes and Zepbound® for weight, tirzepatide pushed average results higher and added indications, including sleep apnea through the SURMOUNT-OSA program. It also broadened the cardiovascular and metabolic evidence base alongside semaglutide’s SELECT trial (Lincoff 2023, NEJM) and the kidney-focused FLOW trial (Perkovic 2024, NEJM).

How Did the Shortage and Compounding Era Begin?

The shortage era began in the early 2020s when demand for semaglutide and tirzepatide outpaced the manufacturers’ supply. With brand drugs hard to get, compounding pharmacies stepped in to prepare the same active molecules, and telehealth made them easy to access.

This was a direct consequence of the weight-loss boom. Once trials proved the dramatic weight effects, demand surged far beyond what production could meet, and the FDA placed the drugs on its shortage list. That shortage status is what legally opened the door for 503A and 503B pharmacies to compound semaglutide and tirzepatide. Telehealth programs grew quickly around this access, offering personalized dosing in vials rather than prefilled pens. The compounding chapter is not a fringe footnote. It is how a large share of patients actually obtained these medications during a period when brand supply could not keep up, and personalization through 503A pharmacies remains a feature of the market.

What Are the Most Recent Milestones?

The most recent milestones include oral semaglutide reaching weight-management doses, the 2026 approval of oral Wegovy®, and the TrumpRx pricing program that set list prices for certain brand GLP-1 drugs. Compounded GLP-1 also became widely available through 503A pharmacies with personalization.

These changes reshaped access as much as the science. An oral version of Wegovy® meant patients could take weight-management semaglutide as a pill rather than an injection. TrumpRx pricing altered the cost comparison between brand and compounded options. Meanwhile, the personalization available through compounding gave telehealth programs a way to tailor dosing to individuals. The class that started with a lizard’s venom is now defined as much by access and delivery as by molecular design.

The pace of these milestones is itself part of the story. A drug class that took decades to get from hormone discovery to its first approval then advanced through weekly dosing, weight indications, outcome trials, a dual-receptor design, oral delivery, and new pricing in roughly half that time. The compression reflects how much momentum gathered once the weight-loss results proved out. For patients, the practical result is more choices than ever in form, dose, and access route, which is also why understanding the options matters.

The Path Forward with GLP-1 Drugs

The arc from a desert lizard to a weekly blockbuster is a story of solving one problem after another: making the hormone last, dosing it less often, then proving its weight effect in dedicated trials. Each step built on the last. A TrimRX program brings this lineage to a personalized plan, pairing compounded semaglutide or tirzepatide with a clinician who understands the evidence behind them. If you want to see how this history applies to you, the free assessment quiz is an easy first step.

FAQ

Did GLP-1 Drugs Really Come From a Lizard?

Partly, yes. The first GLP-1 drug, exenatide, was based on a peptide called exendin-4 found in Gila monster venom. That peptide resembles human GLP-1 but resists the enzyme that destroys the human hormone in minutes, making it durable enough to use as a drug. Later drugs were engineered from human GLP-1 instead.

What Was the First GLP-1 Drug Approved?

Exenatide, sold as Byetta, was approved in 2005 for type 2 diabetes. It was based on the Gila monster venom peptide and dosed twice daily. It proved the concept and was followed by longer-acting drugs like liraglutide and then once-weekly semaglutide.

When Did GLP-1 Drugs Become Known for Weight Loss?

In the early 2020s. Weight loss was a noted side effect in earlier diabetes trials, but the STEP program for semaglutide, published starting in 2021, tested it specifically for obesity at higher doses. The dramatic results led to Wegovy® and shifted the class’s public identity toward weight management.

How Did Dosing Go From Twice Daily to Once Weekly?

Through molecular engineering. The first drug needed twice-daily dosing. Adding a fatty acid chain that binds albumin in the blood slowed clearance, letting liraglutide dose once daily and semaglutide once weekly. This albumin-binding strategy, plus changes that resist the DPP-4 enzyme, is the key advance behind weekly dosing.

What Makes Tirzepatide Different in This History?

Tirzepatide was the first twincretin, activating two gut hormone receptors, GIP and GLP-1, with one molecule rather than just GLP-1. Approved in the 2020s as Mounjaro® and Zepbound®, it produced larger average weight loss in the SURMOUNT trials and expanded the indications and evidence for the class.

What Changed for GLP-1 Drugs in 2026?

Several things. Oral Wegovy® was approved, bringing weight-management semaglutide to a pill. The TrumpRx program set list prices for certain brand GLP-1 drugs, changing the cost picture. Compounded GLP-1 remained widely available through 503A pharmacies with personalized dosing, broadening access beyond brand products.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.